Abstract
The 2014-2016 Ebola virus outbreak in West Africa was the deadliest in history, prompting the evaluation of various drug candidates, including antibody-based therapeutics for the treatment of Ebola hemorrhagic fever (EHF). Prior to 2014, only convalescent blood products from EHF survivors had been administered to newly infected individuals as a form of treatment. However, during the recent outbreak, monoclonal antibody cocktails such as ZMapp, ZMAb and MB-003 were either tested in a human clinical safety and efficacy trial or provided to some based on compassionate grounds. This review aims to discuss the evolution of antibody-based treatments for EHF, their clinical trial efficacy and the development of new antibody-based therapies currently advancing in preclinical testing.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 435-450 |
| Number of pages | 16 |
| Journal | Immunotherapy |
| Volume | 9 |
| Issue number | 5 |
| DOIs | |
| State | Published - Mar 2017 |
| Externally published | Yes |
Keywords
- Ebola virus
- clinical trials
- convalescent plasma
- monoclonal antibodies
- outbreak
- pan-ebolavirus
- pan-filovirus
- therapeutics
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
- Oncology